| AbbVie7 programs in shared conditions | 3Arthritis, Rheumatoid, Carcinoma, Ovarian Epithelial, Waldenstrom Macroglobulinemia | — | - BeOne Medicines’ tacabrutideg vs venetoclax (US & EU rights: AbbVie) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06846671)
- BeOne Medicines’ sonrotoclax in a combination vs venetoclax (US & EU rights: AbbVie) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06943872)
- BeOne Medicines’ sonrotoclax in a combination vs venetoclax (US & EU rights: AbbVie) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06073821)
- and 3 more
|
| Eli Lilly and Company7 programs in shared conditions | 3 · 2 with both in phase 3Breast Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Arthritis, Rheumatoid | tersolisib, Imlunestrant, pirtobrutinib | - BeOne Medicines’ tacabrutideg vs pirtobrutinib (US & EU rights: Eli Lilly and Company) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06973187)
- Eli Lilly and Company’s pirtobrutinib vs zanubrutinib (US & EU rights: BeOne Medicines) (Lymphoma, Mantle-Cell, NCT04662255)
- BeOne Medicines’ CDK4 Inhibitor BGB-43395 in a combination vs abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT07492641)
|
| AstraZeneca13 programs in shared conditions | 6 · 5 with both in phase 3Breast Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Ovarian Epithelial +3 | capivasertib, datopotamab deruxtecan, camizestrant +5 | - BeOne Medicines’ sonrotoclax in a combination vs acalabrutinib (US & EU rights: AstraZeneca) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT07277231)
- BeOne Medicines’ zanubrutinib in a combination vs acalabrutinib (US & EU rights: AstraZeneca) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT07277231)
|
| Hoffmann-La Roche7 programs in shared conditions | 3 · 1 with both in phase 3Breast Neoplasms, Lymphoma, Large B-Cell, Diffuse, Arthritis, Rheumatoid | inavolisib, giredestrant, bizrolertinib +1 | - BeOne Medicines’ sonrotoclax in a combination vs obinutuzumab (US & EU rights: Hoffmann-La Roche) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06073821)
- BeOne Medicines’ zanubrutinib in a combination vs obinutuzumab (US & EU rights: Hoffmann-La Roche) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06073821)
|
| Lupeng Pharmaceutical Ltd.2 programs in shared conditions | 4 · 2 with both in phase 3Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse +1 | rocbrutinib | - Lupeng Pharmaceutical Ltd.’s rocbrutinib vs zanubrutinib (US & EU rights: BeOne Medicines) (Lymphoma, Mantle-Cell, NCT07377578)
|